Brian Joseph Cahill - 27 Feb 2024 Form 4 Insider Report for EAGLE PHARMACEUTICALS, INC. (EGRX)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: EGRX
Reported as of: 27 Feb 2024
Net transaction value: -$10,233
SEC form: 4
Accepted by SEC: 29 Feb 2024, 20:23:05 UTC
Prior SEC filing: 06 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Brian Cahill

Key filing fact

Brian Joseph Cahill filed Form 4 for EAGLE PHARMACEUTICALS, INC. (EGRX) on 29 Feb 2024.

Key facts

This page summarizes Brian Joseph Cahill's Form 4 filing for EAGLE PHARMACEUTICALS, INC. (EGRX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 29 Feb 2024, 20:23.

Change

Previous filing in this sequence was filed on 06 Feb 2024.
Current net transaction value: -$10,233.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EGRX transaction

Common Stock

Award

Transaction value: $0
Shares: +3,800
Change %: +8.3%
Price: $0.000000
Shares after: 49,547
Date: 27 Feb 2024
Ownership: Direct
Footnotes: F1

EGRX transaction

Common Stock

Tax liability

Transaction value: $10,233
Shares: -1,589
Change %: -3.2%
Price: $6.44
Shares after: 47,958
Date: 27 Feb 2024
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents common stock issued upon satisfaction of certain performance criteria contained in performance stock units ("PSUs") granted in 2021.

Footnote F2

The disposition reported on this Form 4 represents shares withheld by the Issuer to cover the tax liability upon the vesting of the PSUs and does not represent a discretionary transaction by the Reporting Person.